Latest news

• South African variant reduces antibody levels produced by Pifzer/BioNTech’s COVID-19 vaccine

  Researchers noted it is 'unclear' what effect this reduction has on the vaccine's protection against the variant

• Pfizer/BioNTech to develop a booster dose for their COVID-19 vaccine

  BioNTech is also planning to publish an additional analysis of its Pifzer-partnered vaccine's efficacy against the coronavirus strain identified in South Africa.

• Pfizer/BioNTech's COVID-19 vaccine found to be effective against UK virus variant

  BioNTech is planning to publish analysis on vaccine's efficacy against South African variant

• Pifzer, BioNTech eye October approval for mRNA-based COVID-19 vaccine

  Companies share additional phase 1 safety and tolerability data

• CHMP recommends new Keytruda dosing schedule

  Other PD-1/PD-L1 inhibitors approved for use are AstraZeneca’s Imfinzi, Pifzer and Merck’s Bavencio and Roche’s Tecentriq, and the latter is currently being explored in a